Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

Abbott (ABT) announced late-breaking data from its Triluminate Pivotal trial that show the TriClip transcatheter edge-to-edge repair system to ...

Partial heart transplants provide a range of lifesaving options for children with complex congenital heart conditions, and ...

When this happens, the heart has to work harder to pump ... is used to place one or more tiny clips on the tricuspid valve leaflets to prevent blood from leaking back into the right atrium.

system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the ... valve leaflets to prevent blood from leaking back into the right atrium.

Sustained Benefits for Patients With Severe Leaky Heart Valve After two years, the TRILUMINATE Pivotal study found TriClip continued to demonstrate superiority compared to medical therapy while ...